Surgeons and health system leaders are voicing concerns about the unknown long-term risks of GLP-1 receptor agonists, such as Ozempic, Wegovy and Saxenda.
The last few years have been tough on spine device companies, but with innovation and value-based care initiatives, opportunities for advancement remain. Learn
Amid the minimal data, physicians have conflicting opinions about stopping GLP-1 regimens before surgeries. The American Society of Anesthesiologists and the American Gastroenterological Association weigh in.
Former rheumatologist at Boston-based Brigham and Women s Hospital accused of performing inappropriate pelvic and breast exams on patients faces over 100 lawsuits